Article
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
Pathology - 1 Feb 2022
Scolyer Richard A, Atkinson Victoria, Gyorki David E, Lambie Duncan, O'Toole Sandra, Saw Robyn P M, Amanuel Benhur, Angel Christopher M, Button-Sloan Alison E, Carlino Matteo S, Ch'ng Sydney, Colebatch Andrew J, Daneshvar Dariush, Pires da Silva Inês, Dawson Tamara, Ferguson Peter M, Foster-Smith Erwin, Fox Stephen B, Gill Anthony J, Gupta Ruta, Henderson Michael A, Hong Angela M, Howle Julie R, Jackett Louise A, James Craig, Lee C Soon, Lochhead Alistair, Loh Daphne, McArthur Grant A, McLean Catriona A, Menzies Alexander M, Nieweg Omgo E, O'Brien Blake H, Pennington Thomas E, Potter Alison J, Prakash Saurabh, Rawson Robert V, Read Rebecca L, Rtshiladze Michael A, Shannon Kerwin F, Smithers B Mark, Spillane Andrew J, Stretch Jonathan R, Thompson John F, Tucker Paul, Varey Alexander H R, Vilain Ricardo E, Wood Benjamin A, Long Georgina V
Abstract excerpt
Targeted therapy (BRAF inhibitor plus MEK inhibitor) is now among the possible treatment options for patients with BRAF mutation-positive stage III or stage IV melanoma. This makes prompt BRAF mutation testing an important step in the management of patients diagnosed with stage III or IV melanoma; one that can help better ensure that the optimal choice of systemic treatment is initiated with minimal delay. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.